Lipoxygenase and cyclooxygenase metabolism: new insights in treatment and chemoprevention of pancreatic cancer

The essential fatty acids, linoleic acid and arachidonic acid play an important role in pancreatic cancer development and progression. These fatty acids are metabolized to eicosanoids by cyclooxygenases and lipoxygenases. Abnormal expression and activities of both cyclooxygenases and lipoxygenases have been reported in pancreatic cancer. In this article, we aim to provide a brief summary of (1) our understanding of the roles of these enzymes in pancreatic cancer tumorigenesis and progression; and (2) the potential of using cyclooxygenase and lipoxygenase inhibitors for pancreatic cancer treatment and prevention.


Review
Molecular studies of the well-known relationship between polyunsaturated fatty acid metabolism and carcinogenesis have revealed novel molecular targets for cancer chemoprevention and treatment [1][2][3][4]. Polyunsaturated fatty acids are esterified in membrane phospholipids and triglycerides in all mammalian tissues [5]. In this form, they are usually not substrates for metabolizing enzymes, but serve the function of sustaining membrane fluidity as well as that of substrate storage [5]. Oxidative metabolism of these fatty acids to prostaglandins, hydroxy-fatty acids and leukotrienes, collectively referred to as eicosanoids, depends on the availability of free, non-esterified fatty acids [5]. These fatty acids are substrates for three distinctively different enzymatic pathways, cyclooxygenase (COX), lipoxygenase (LOX) and epoxygenase [5]. This article presents a new perspective about the role of cyclooxygenase and lipoxygenase on pancreatic cancer development and growth, the underlying mechanisms by which they mediate these effects and their potential as targets for pancreatic cancer prevention and treatment. ulated in many cancer types, including the colon, breast, lung, pancreas, and esophagus as well as squamous cell carcinoma of the head and neck [7][8][9][10][11]. COX-2 specific inhibitors inhibit cell growth in a number of tumors including skin, colonic, gallbladder, esophageal and pancreatic cancer cells [7][8][9][10][11]. Studies from both COX-2 transgenic and COX-2 knockout mice confirm that COX-2 plays a key role in colonic cancer development [12]. However, a recent study in COX-1 deficient mice, showed that lack of COX-1 also significantly reduced intestinal tumorigenesis in min mice, a phenotype similar to that of COX-2 -/mice [12]. Furthermore, there may be other forms of COX enzymes, making things even more complicated. Simmons and colleagues, recently identified an enzyme that they have called cyclooxygenase-3, or COX-3. COX-3 is an isoform of COX-1, but is expressed in cells in an inducible manner [13]. COX-3 is selectively inhibited by different NSAIDs and has a high sensitivity to acetaminophen. However, whether COX-3 is involved in tumorigenesis is unknown [13].
Three forms of 12-lipoxygenase have been identified, including the leukocyte-type and platelet-type (both 12(S) LOXs) as well as an epidermal form (also called 12(R) LOX), with differences in tissue localization, substrate specificities, immunogenicities and sequence homology [14,15]. The "platelet-type" 12-LOX converts arachidonic acid to 12-(S)-HETE while the "leukocyte type" 12-LOX metabolizes arachidonic acid or linoleic acid to either 12(S)-HETE or 15(S)-HETE [14,15]. Both the leukocytetype and platelet-type12-LOX have been found in different cancer tissues, including melanoma, prostate and epidermal cancers [18]. Evidence indicates that 12-LOX is involved in both cancer cell proliferation and survival [15]. Inhibition of 12-LOX with either 12-LOX inhibitors or a 12-LOX antisense oligonucleotide inhibits proliferation and induces apoptosis in carcinosarcoma cells, while adding back the 12-LOX metabolite, 12(S)-HETE prevents 12-LOX inhibitor-induced apoptosis [22]. Expression of 12-LOX is also correlated with tumor cell metastasis. 12(S)-HETE directly stimulates prostate cancer cell migration. Clinically, the degree of 12-LOX expression in human prostate cancer correlates with the tumor grade and stage and 12-LOX expression level is higher in metastatic prostate cancers than in nonmetastatic ones [23].
Another arachidonic acid-metabolizing enzyme is 8lipoxygenase, which was cloned recently. This enzyme is expressed in the skin after irritation or treatment with tumor promoters [25]. To understand the function of the product of 8-lipoxygenase, 8-hydroxyeicosatetraenoic acid transgenic mice have been generated [26]. These animals show enhanced differentiation of epidermal keratinocytes along with enhanced proliferation of the basal cell population. While the function of 8-HPETE and 8-HETE are unknown, their importance in tumor promoterelicited events is suggested by the finding that application of the lipoxygenase inhibitor, eicosatetraenoic acid maximally inhibits tumor promotion when applied at the time of maximum induction of 8-lipoxygenase [26,27]. Compared with other LOX enzymes, 8-LOX has received little attention for its role in carcinogenesis and cancer growth.
Expression and function of 8-LOX in pancreatic cancer have not been investigated to date even though 8-LOX cDNA and antibody are available [27]. 15-lipoxygenase, which is distributed widely in tissues, converts arachidonic acid to 15-HPETE which is then reduced by glutathione peroxidase to 15-HETE [16,17,24,28]. There are two 15-LOX isoenzymes, 15-LOX-1 and 15-LOX-2 [28]. The preferred substrate for 15-LOX-1 is linoleic acid and for 15-LOX-2 is arachidonic acid. 15-LOX-1 metabolizes linoleic acid to 13-S-HODE, which differs from 15-LOX-2 which, as expected, converts arachidonic acid to 15-HETE [28]. The role of 15-LOX in cancer development is unclear and somewhat controversial [28]. A series of studies from one group suggest that the 15-LOX-1 product, 13-S-HODE enhances colonic tumorigenesis. 13-S-HODE enhances cell proliferation and potentiates the mitogenic response to EGF in different cell types [29,30]. These proposed effects, however, are not consistent with other reports that 13-S-HODE did not enhance EGF-dependent DNA synthesis [28]. Indeed, Lippman et al reported that 13-S-HODE induces apoptosis and cell cycle arrest in colorectal cancer cells [31]. Evidence also indicates that 15-S-HETE may have anti-tumorigenic effects by antagonizing other LOX products, such as LTB 4 and 12-S-HETE [28]. 15-HETE inhibits LTB 4 production and reduces LTB 4 binding to its receptors and thereby blocks cellular responses to LTB 4 . 15-HETE also blocks platelet-type 12-LOX activity and reduces 5-LOX activity in rat basophilic leukemia cells [28,32]. Different studies have suggested that 15-S-HETE may suppress apoptosis, or have no effect on apoptosis in cancer cells [28]. A recent study has shown that 15-S-HETE inhibits proliferation in PC3 prostate carcinoma cells, possibly through activation of PPARγ [33]. Therefore, further studies are required to clarify the role of 15-LOX in tumorigenesis and cancer growth.

COX inhibition and pancreatic cancer incidence, the epidemiological observations
Tumorigenesis is a complex process and understanding its mechanisms is the key to designing effective targeted therapies. Several epidemiologic studies have shown an inverse correlation between the incidence of colon cancer and the use of nonsteroidal anti-inflammatory drugs (NSAIDs), which inhibit prostaglandin synthesis [8]. Because COX-2 is frequently over-expressed in premalignant lesions and neoplasms, specific COX-2 inhibitors have been investigated as chemo-preventive and potential chemotherapeutic agents [6][7][8]. New preclinical and early clinical data suggest, that inhibitors of COX-2 may protect against colon, breast, lung, esophageal, and oral tumors [8]. Even though epidemiological studies on the role of NSAIDs in pancreatic cancer incidence are not as detailed as in colonic cancer, evidence does suggest that NSAIDs might decrease the incidence of pancreatic cancer [34]. Recently, Anderson and colleagues [34] from University of Minnesota investigated the association between pancreatic cancer and aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) in 28283 participants. Multivariate analysis suggested that women who used aspirin had a 43% lower risk of pancreatic cancer compared with those who did not use aspirin. Furthermore, the association appeared to be related to the dose; women who took aspirin 2-5 times a week had a 53% lower risk, and those who took aspirin six or more times a week had a 60% lower risk than women who never took aspirin. In contrast to COX inhibitors, epidemiological evidence regarding the effect of LOX inhibitors on pancreatic cancer incidence is lacking, since specific LOX inhibitors have only recently become available in the clinic.

Expression of COX and LOX in pancreatic cancer
COX-2 is only expressed in pancreatic islets and has no expression in normal exocrine pancreatic tissues [35]. A considerable amount of evidence from several clinical studies in the United States and Japan supports that COX-2 is upregulated in pancreatic adenocarcinoma. Studies that demonstrate this have employed RT-PCR, quantitative RT-PCR, in situ hybridization, western blotting and immunohistochemistry [36][37][38][39][40][41][42]. One report showed that levels of COX-2 mRNA were more than 60-fold increased in pancreatic cancer compared to adjacent non-tumor tissue [36]. The COX-2 protein was detected in 90% of pancreatic adenocarcinomas [36]. In general, studies suggest that COX-2 is weakly expressed in benign pancreatic adenoma, but dramatically up-regulated in pancreatic adenocarcinoma, even though extent of COX-2 expression differs from one study to another [36][37][38][39][40][41][42]. Expression of COX-2 has been demonstrated in several pancreatic cancer cell lines, although once again there is a lack of consistency between different studies [38,43]. Nzeako and Gores, analyzed possible reasons for the inconsistent reporting of COX-2 expression by different groups [44]. Firstly, the lack of correlation in immunohistochemical staining intensity for COX-2 may result from working with previously fixed and embedded tissue, the fixation methods used and the duration of fixation. The process of fixing and embedding can destroy or denature cellular proteins, thereby altering antigenic recognition by immunohistochemistry [44]. Under such circumstances, attempts at correlating staining intensity with other variables are very likely to yield spurious results. In this situation, more reliable results may be obtained using frozen tissues with a standardized fixation procedure. Secondly, the use of polyclonal antibodies for immunohistochemistry may diminish reliability, since other tissue proteins may be inadvertently stained [44].
Despite these inconsistencies, all of these studies indicate that COX-2 is over-expressed in pancreatic cancer. A recent study showed, that perineural invasion was associated with COX-2 expression in pancreatic cancer and increased COX-2 expression was more common in the glandular component than the solid component of the tumors [41]. Regarding expression of COX-2 in early neoplastic lesions of the pancreas, researchers from John Hopkins immunohistochemically examined expression of COX-2 in adenocarcinomas, pancreatic intraepithelial neoplasia [PanIN] and normal pancreatic ducts with an automated platform [42]. The overall percentage of positive cells was 47.3% in adenocarcinomas, 36.3% in PanINs and 19.2% in normal ducts. COX-2 was expressed in more than 20% of cells in 23 adenocarcinomas (77%), 42 PanINs (65%), and 12 normal ducts (40%). Significant differences in COX-2 expression were demonstrable in both adenocarcinomas vs normal ducts and PanINs vs normal ducts [42]. The up-regulation of COX-2 in a subset of noninvasive precursor lesions makes it a potential target for chemoprevention using selective COX-2 inhibitors.
Expression of LOX is also up-regulated in both adenocarcinomas and early neoplastic lesions of the pancreas. Reverse transcriptase-polymerase chain reaction revealed expression of 5-LOX mRNA in all of the commonly used pancreatic cancer cell lines, including PANC-1, AsPC-1, and MiaPaCa2 cells, but not in normal pancreatic ductal cells [45]. The expression of the 5-LOX protein in pancreatic cancer cell lines was confirmed by western blotting [46]. 5-LOX up-regulation in human pancreatic cancer tissues was verified by immunohistochemistry, which revealed intense positive staining in cancer cells [46]. Staining of the 5-LOX protein was particularly evident in the ductal components of the more differentiated tumors but, in contrast, ductal cells in normal pancreatic tissues from organ donors did not stain. Immunohistochemistry also revealed strong staining of cancer tissues with an antibody to the receptor of the downstream 5-LOX metabolite, leukotriene B4 [46]. It also appears that levels of 5-LOX in hepatic metastases of pancreatic cancer express more 5-LOX than the primary tumors [46]. These findings provide further evidence of up-regulation of this pathway in pancreatic cancer and suggest that LOX inhibitors are likely to be valuable for the treatment or prevention of this dreadful disease.
There is also RT-PCR evidence of 12-LOX expression in pancreatic cancer cell lines [45]. Expression of 12-LOX in pancreatic islets has been reported and it is not yet clear, whether 12-LOX is expressed or up-regulated in pancreatic cancer [47]. Whether 15-LOX and 8-LOX are expressed in pancreatic cancer or in normal pancreatic tissues has not been investigated.

Effects of COX and LOX inhibition on pancreatic cancer growth and apoptosis: In vitro and in vivo studies
The effects of COX inhibition on pancreatic cancer growth has been examined both in vitro and in vivo, using both non-specific NSAIDs and specific COX-2 inhibitors. The effect of these inhibitors depends, at least in part, on the COX-2 pathway in cultured pancreatic cancer cell lines [48]. One study showed that COX inhibitors significantly suppressed proliferation of cells that have high levels of COX-2 expression, but exerted minimal effects on proliferation in cells with a significantly lower level of COX-2 [48]. We have reported that the non-specific COX inhibitor, indomethacin is equally potent in inhibiting pancreatic cancer cell proliferation compared with the specific COX-2 inhibitor, NS398 [43].
Another important action of the COX-2 enzyme is inhibition of apoptosis, which in many cases constitutes another mechanism to promote tumor cell growth. Several studies have revealed that COX-2-specific and non-specific NSAIDs induce apoptosis in a variety of cancer cells, including colon, gastric, glioma, and lung cancer cells [6][7][8].
Recently, we and others have demonstrated that COX inhibitors significantly induce apoptosis in pancreatic cancer cells [43]. Non-specific NSAIDs and COX-2 specific inhibitors were also equipotent for inducing apoptosis, suggesting that the COX-2 pathway plays a key role in preventing apoptosis and that NSAIDs reverse this effect by inhibiting the pathway [43]. Pancreatic cancer growth is inhibited by COX-2 in animal models as well as in vitro. Our data show that the COX-2 inhibitor, celecoxib significantly decreases both volume and weight of pancreatic tumors xenografted subcutaneously into nude mice.
Compared with the investigations on the role of COX in the development and growth of cancers, information regarding the role of lipoxygenases in the regulation of pancreatic cancer growth is limited. Studies conducted by Anderson et al showed inhibition of pancreatic cancer cell proliferation following treatment with the 5-lipoxygenase activating protein (FLAP) inhibitor, MK886 [49][50][51]. Coincident with growth inhibition, changes in expression of several genes, including tumor suppressor genes and growth factor receptors were induced by MK886 [50]. Anderson et al reported that MK886 induces an "atypical" apoptosis in PANC-1 pancreatic cancer cells which is enhanced by gamma linolenic acid [51]. We recently explored the effect of LOX inhibition on pancreatic cancer cell proliferation and survival using pharmacological LOX inhibitors and a FLAP inhibitor, as well as antisense oligonucleotides targeting 5-LOX, 12-LOX or 15-LOX expression [45,52]. Blockade of either 5-LOX or 12-LOX markedly inhibited cell proliferation and induced apoptosis in all of the pancreatic cancer cell lines studied. Apoptosis induced by blockade of either the 5-LOX or 12-LOX enzyme was documented by propidium iodide DNA staining, demonstration of DNA fragmentation by electrophoresis as well as by the TUNEL assay [45,52]. Antisense oligonucleotides directed against both 5-LOX and 12-LOX had similar inhibitory effects on pancreatic cancer cell proliferation to the small drug LOX inhibitors. In contrast, 15-LOX does not appear to play any important role in pancreatic cancer cell growth, since transfection of 15-LOX antisense oligonucleotide did not affect DNA synthesis of pancreatic cancer cells in our studies [45]. These studies support the potential use of LOX inhibitors in pancreatic cancer treatment or prevention. Animal experiments conducted in our laboratory indicate that blockade of LOX pathways also inhibits growth of pancreatic cancers xenografted into athymic nude mice [53,54]. While the study conducted by Anderson et al showed that blockade of 5-LOX induced only an "atypical" apoptosis, our data clearly show that apoptosis is induced by LOX enzyme inhibition [52]. The reasons for these different results are not clear. To confirm that apoptosis occurs in pancreatic cancer cells following LOX inhibitor treatment, we conducted further studies that showed that LOX inhibitors reduce expression of Bcl-2 and Mcl-1 and induce activation of caspase-3 and -9 as well as cleavage of the caspase-3 target, PARP [53,54].

Prevention of pancreatic cancer with COX and LOX inhibitors
Pancreatic carcinoma can be induced in hamster models by administering N-nitrosobis(2-oxopropyl)amine (BOP). This animal model mimics human pancreatic cancer biologically and genetically, including mutated k-Ras, desmoplasia and insulin resistance [55][56][57]. Takahashi et al treated hamsters with BOP and then subsequently treated them with the non-selective COX inhibitors, indomethacin or aspirin [58]. Animals in the indomethacin group developed significantly fewer tumors than the control group. Aspirin also had a tendency to decrease the incidence of pancreatic cancers [58]. Using the same pancreatic cancer model, Wenger et al reported that the specific COX-2 inhibitor, celebrex also prevented pancreatic cancer [59].
Several excellent studies support the use of COX inhibitors for preventing cancer of different organs including colon, lung, breast and pancreas, while exploration of the potential for LOX inhibitors as chemopreventive agents is just beginning. It was recently reported that 5-LOX pathway inhibitors, accolate, MK-886, zileuton, and combinations of zileuton with either accolate or MK-886 reduced lung tumor multiplicity by 37.8, 29.5, and 28.1%, respectively following injection of lung cancer carcinogen vinyl carbamate into mice [60]. These inhibitors also decreased the size of the tumors and the yield of carcinomas [60]. An extract from the sea cucumber, Cucumaria frondosa which is a potent LOX inhibitor, attenuates pancreatic cancer development. In our recent study, hamsters were fed with an extract of sea cucumber for one week before pancreatic cancer cells were transplanted orthotopically into the pancreas. The extract decreased pancreatic cancer incidence as well as tumor size.

Mitogenic effects of COX and LOX metabolites
Evidence suggests that the prostaglandin products of the COX pathway, especially PGE2 enhance cell proliferation in either normal and cancer cells through specific receptors [61][62][63][64][65][66][67]. Prostaglandins exert their effects locally in both an autocrine and paracrine manner. PGE 2 receptors are a family of G-protein-coupled receptors, namely, EP 1 , EP 2 , EP 3 , and EP 4 [68]. Functional studies on the EP receptors have relied on use of EP knockout mice. The deficiency of the prostaglandin receptor EP 2 gene reduced the size and number of intestinal tumors in APC 716 mice, similar to deficiency of the COX-2 gene [69]. Besides prostaglandin E2 and its receptor, thromboxane A2 is also involved in cancer development [70][71][72][73][74][75]. Thromboxane A2 enhances cancer cell proliferation, while its antagonist blocks cancer cell growth. We have shown that both 5-LOX and 12-LOX are also involved in pancreatic cancer cell proliferation. Both 5-HETE and 12-HETE enhance DNA synthesis in pancreatic cancer cells by activating multiple intracellular signal pathways [76-78]. Our most recent study suggests that LTB4 receptors are up-regulated in human pancreatic cancer tissues and coincidentally, pancreatic cancer cells produce LTB4 [46]. This autocrine loop might be important for pancreatic cancer cell growth, as LTB4 itself stimulates pancreatic cancer cell growth while the LTB4 receptor antagonist, LY293111 blocks growth of pancreatic cancer both in vitro and in vivo [79]. The signaling pathways that respond to COX and LOX-derived metabolites in cancer cells include ERK1/2, PI3 kinase/AKT cascade, tyrosine kinases, STAT, c-Myc and others which are summarized in Table 1.

Regulation of cell survival by COX and LOX
Inhibition of either COX or LOX induces apoptosis of pancreatic cancer cells while forced expression of COX-2 prevents apoptosis. Multiple cellular proteins are involved in this process and mitochondria are the key organelles for COX or LOX inhibition-induced apoptosis [83][84][85][86]. Treatment of cancer cells with COX inhibitors induces cytochrome C release from mitochondria, which in turn activates caspase-9 and then caspase-3 [83-86]. Cytochrome C release seems to be directly related to COX inhibition since addition of prostaglandin E2 can prevent NS398-induced cytochrome C release, caspase activation and PARP cleavage [83][84][85][86]. Other studies have shown that over-expression of COX-2 increases Bcl-2 expression, which might be responsible for preventing cytochrome C release from mitochondria [87]. A recent study showed that death receptors are also involved in COX-regulated cancer cell survival [88][89][90]. Forced COX-2 expression significantly attenuated TRAIL-induced apoptosis and was associated with transcriptional repression of death receptor-5 and up-regulation of Bcl-2 [89]. Over-expression of COX-2 also reduced caspase-8, caspase-3, and caspase-9 activation relative to corresponding parental cells [89]. In contrast, COX inhibitors were able to restore death receptor-5 expression. Several lines of evidence suggests that NFκB and PI3 kinase are involved in NSAID-induced cancer cell apoptosis [89]. NSAIDs inhibit NFκB and PI3 kinase activity, while restoration of NFκB or PI3 kinase activity blocks NSAID-induced apoptosis [91][92][93]. Inhibition of COX-2 causes an increase in tissue concentrations of ceramide. Since ceramide is an effective inducer of apoptosis, metabolism of arachidonic acid by COX-2 might prevent apoptosis by reducing intracellular ceramide concentrations. Therefore, an imbalance between PGE2 and ceramide may contribute to the apoptosis-preventing effects of COX-2 in cancer cells [94,95]. The mechanisms involved in COX-mediated cancer cell survival are complex and it is likely that even more pathways involved in these effects will be identified in the future.
To date, three signal cascades have been shown to be linked to LOX-regulated pancreatic cancer cell survival. The first pathway is the Bcl protein family-release of cytochrome C from mitochondria-caspase cascade [53,54,[96][97][98]. Treatment of pancreatic cancer cells with either 5-LOX or 12-LOX inhibitors, dramatically upsets the balance between the anti-apoptotic proteins (such as Bcl-2, Mcl-1) and the pro-apoptotic protein (Bax). This in-creased pro/anti-apoptotic protein ratio triggers cytochrome C release from mitochondria, which in turn activates caspase cascade and results in apoptosis. The second cascade is the extracellular regulated kinase cascade (MEK/ERK). It is known that activation of the MEK/ERK signal transduction pathway prevents apoptosis. Our studies show that the LOX metabolites, 5-HETE, 12-HETE and LTB4 stimulate MEK/ERK phosphorylation [76-78,80]. PI3 kinase/AKT protects cells from apoptosis by phosphorylation of Bad. Bad is a pro-apoptotic member of the Bcl-2 family that can displace Bax from binding to Bcl-2 and Bcl-xL, resulting in cell death. Phosphorylation of Bad results in its binding to 14-3-3 proteins and prevents it binding to Bcl-2 and Bcl-xL. We have shown that both 5-HETE and LTB4 activate the PI3 kinase/AKT cascade, which constitutes the third pathway which links LOX activation to the prevention of apoptosis in pancreatic cancer cells [78][79][80].

Modulation of cell migration, invasion and angiogenesis
It is well documented that COX inhibitors reduce cancer cell migration, cell adhesion and tumor invasiveness [6,7,99]. In contrast, constitutive COX-2 expression leads to enhanced cell invasiveness [100,101]. The biochemical changes associated with over-expression of COX-2 include increased expression and activation of metalloproteinase-2 (MMP-2) and reduced expression of E-cadherin [102][103][104]. We speculate that there are likely to be several pathways that mediate COX-2-promoted cell invasion, which may be cell-type dependent. The multiple effects of COX-2 on cell motility and cell adhesion suggest a key role for COX-2 in tumor invasiveness and angiogenesis.
Both non-specific and specific COX-2 inhibitors significantly inhibit angiogenesis, a process that involves inacti- vation of the MAPK pathway. COX-2 induces the production of vascular endothelial growth factor (VEGF), a proangiogenic growth factor. This induction is blocked by a COX-2 specific inhibitor, NS-398 [105][106][107]. Recently, the molecular mechanism for COX-2-mediated VEGF expression has been elucidated. A large amount of PGE 2 is generated when COX-2 expression is induced or over-expressed in pancreatic cancer. Activation of the PGE 2 surface membrane receptors increases intracellular cAMP, in turn stimulating VEGF production and thereby promoting neovascularization and tumor angiogenesis [108]. Separate studies suggest that other products of the COX pathway, thromboxane A 2 and PGI 2 also promote angiogenesis [72,75,109,110]. The thromboxane A2 analogue, U46619, stimulates endothelial cell migration [72]. On the other hand, basic fibroblast growth factor (bFGF) or vascular endothelial growth factor (VEGF), which are angiogenic, increase thromboxane A2 synthesis [111][112][113]. In contrast, inhibition of thromboxane A2 synthesis reduces HUVEC migration stimulated by VEGF or bFGF [75,114]. Furthermore, the thromboxane A2 receptor antagonist inhibits VEGF-or bFGF-stimulated endothelial cell migration and bFGF-induced angiogenesis in vivo [75,114].
LOX activity is required for serum-and bFGF-stimulated endothelial cell proliferation and for modified low-density lipoprotein-induced monocyte binding to endothelial cells [115]. 12(S)-HETE can directly stimulate endothelial cell mitogenesis, migration and surface expression of integrin [115][116][117][118]. In addition to its role in endothelial cell migration, 12-LOX is also involved in endothelial cell differentiation, seen as tube formation [115]. Pretreatment of endothelial cells with the 12-LOX inhibitor, BHPP inhibits the formation of these vessel-like structures in Matrigel. Exogenous 12(S)-HETE can induce a reversible retraction of endothelial cell monolayers cultured on collagen by regulating PKC [115][116][117][118]. The involvement of 12-LOX in endothelial cell angiogenic responses seen in vitro has been confirmed in vivo, by the observation that the 12-LOX inhibitor, BHPP significantly reduces bFGFstimulated angiogenesis [115]. The role of 12-LOX in endothelial cell proliferation, together with the finding that 12-LOX is involved in endothelial cell migration and differentiation, implicate the mobilization of arachidonic acid and the generation of 12(S)-HETE in endothelial cells as an early event in the intracellular cascade of angiogenic responses. We have reported that levels of 5-LOX in metastatic pancreatic cancer are higher than in non-metastatic tumor. However, there is little information on the role of 5-LOX on the regulation of angiogenesis and cancer metastasis.

Immune suppression
Individuals at high risk for pancreatic cancer include smokers, and persons with all forms of chronic alcoholic, metabolic, tropical or hereditary pancreatitis. The duration of exposure to inflammation seems to be the major factor involved in the transition from benign to malignant condition [119][120][121][122]. Cytokine-mediated up-regulation of COX-2 contributes to increased synthesis of PGs in inflamed tissues [119][120][121][122]. The occurrence and growth of various tumors are associated with immune suppression and prostaglandin E2 itself is a potent immunsuppressor [119][120][121]. Not only do cancer cells themselves produce prostaglandins, but factors released from tumor cells activate monocytes and macrophages to synthesize PGE 2 . In turn, PGE 2 inhibits the production of immune regulatory lymphokines, T-cell and B-cell proliferation, and the cytotoxic activity of natural killer cells, thus favoring tumor growth [119][120][121]. PGE 2 also inhibits the production of tumor necrosis factor-α and induces the production of IL-10, an immunosuppressive cytokine [119][120][121][122][123]. Recently, more molecular mechanisms for PGE 2 -mediated immunosuppression have been revealed. For example, PGE2 suppressed IL-15-mediated human natural killer cell function [123].

Free radicals and peroxidation
Nitric oxide (NO) is a short-lived molecule required for many physiological functions which is produced from Larginine by NO synthases (NOS) [124]. It is a free radical, producing many reactive intermediates that account for its bioactivity [124]. Sustained induction of the inducible form of NOS (iNOS) in chronic inflammation may be mutagenic, either through NO-mediated DNA damage or by hindering DNA repair. Thus sustained NO production is potentially carcinogenic [124]. Progression of the majority of human and experimental tumors appears to be stimulated by NO resulting from activation of iNOS or constitutive NOS [124]. NO can stimulate tumor growth and metastasis by promoting migration and invasion, which may also be triggered by activation of cyclooxygenase [125,126]. Furthermore, iNOS is induced by COX-2 and there is a significant correlation between positive COX-2 and iNOS expression in cancer tissues [125,126].
Both COX and LOX enzymes are peroxidases. It has been proposed that the peroxidase activity of these enzymes may catalyze the conversion of procarcinogens into carcinogens [127][128][129][130][131][132][133][134]. In the liver, such oxidative reactions are catalyzed principally by cytochrome P-450s. However, pancreatic tissues and other organs frequently have low concentrations of P-450s and, therefore, significant amounts of xenobiotics may be co-oxidized to mutagens by the peroxidase activities of COX and LOX [126]. In addition to catalyzing the synthesis of mutagens, both COX-2 and LOX can be induced by carcinogens, such as NNK and BOP [131][132][133][134]. Our unpublished data show that both 5-LOX and 12-LOX are induced in pancreatic ductal cells following treatment with BOP or NNK. Other studies showed that carcinogens induce COX-2 expression and COX-2 in turn catalyzes the oxidation of procarcinogens to produce a highly reactive and strongly mutagenic compounds [132,127,133]. Taken together, these findings suggest a role for COX-2 or LOX inhibitors in preventing carcinogen-induced DNA damage, thereby preventing cancer development.

Feasibility of targeting cyclooxygenase and lipoxygenase for treatment and prevention of pancreatic cancer
The requirements for a chemopreventive drug are that it must have specific targets that are highly expressed in precancer or cancer cells. Such an agent should not be toxic and not disrupt normal cellular functions. Both COX-2 and LOX are up-regulated in cancer and genetic knockouts of these targets do not appear to disrupt normal functions of mice, although there is loss of inflammatory function. These enzymes should, therefore, be ideal targets for pancreatic cancer treatment and chemoprevention. Indeed, COX-2 inhibitors are already being used clinically for colon cancer prevention. Molecular studies indicate that carcinogenesis is a multistep (accumulated genetic and epigenetic alterations), multipath (multiple functional pathways) and multifocal process, frequently driven by genetic instability. Therefore, a combination of drugs with different targets is likely to enhance the efficiency of cancer treatment and chemoprevention. We believe that a combination of COX and LOX inhibitors will yield better results in pancreatic cancer treatment and prevention. Although this approach needs to be confirmed in future studies. Development of drugs targeting both enzymes would be another useful future direction for cancer treatment and prevention.
Several compounds that have either anti-COX or anti-LOX activities have been identified from natural products or food supplements. For example, a polyphenol isolated from the skins of grapes, resveratrol has been shown to be a potent anti-pancreatic cancer agent and is also a COX inhibitor [135]. Ajoene, a garlic-derived natural product that interfaces with the COX-2 enzyme, has anti-cancer activities [136,137]. Other anti-COX-2 agents extracted from green tea and certain herbal medicines also have effects on cancer development [138,139]. Recently, we found that a polar lipid isolate from sea cucumbers markedly blocks pancreatic cancer cell proliferation and induces apoptosis. The anti-pancreatic cancer activity of this extract is probably mediated through inhibition of LOX activity, since it inhibits LTB4 secretion. Furthermore, adding LOX metabolites blocks the inhibitory effect of this extract on pancreatic cancer cell proliferation. These natural products are likely to be valuable in preventing pancreatic cancer development if we could identify high risk pancreatic cancer populations, since these natural products are available in the food chain.
There are, of course, certain problems which need to be solved before the use of COX and LOX enzyme inhibitors can be translated into the clinic for pancreatic cancer treatment and prevention. The specificity of drugs is an important issue facing clinicians [140]. Even though it is claimed that celecoxib and other compounds are specific COX-2 inhibitors, the interpretation of COX-2 studies is complicated by possible COX-2-independent mechanisms [140]. In some cases, NSAIDs only induce apoptosis at concentrations that are much higher than their IC 50 s [140]. In addition, NSAIDs have been shown to trigger apoptosis in COX-2 deficient cells and NSAID metabolites that do not inhibit COX, such as sulindac sulfone, can also cause apoptosis by inhibiting cGMP-dependent phosphodiesterase [140]. Therefore, the cancer inhibitory effects of COX-2 inhibitors seem to involve COX-2 independent mechanisms [140]. With regard to LOX inhibitors, none of these have yet reached the clinic for testing of anti-cancer activity.
There still is debate about the specific role of COX-2 in cancer development. It is indeed that COX-2 over-expression increases tumor growth and that the COX-2 protein is strongly induced in cancer cells. However, COX-1 may have an important role in cancer prevention as suggested by the COX-1-deficient Min mice. When Min mice were treated with celecoxib or the conventional NSAID piroxicam, the number of tumors per animal was significantly reduced. Knocking out the COX-2 gene resulted in an 8fold reduction in the intestinal tumor burden. However, COX-1-deficient Min mice exhibit similar decreases in intestinal tumorigenesis as COX-2-null Min mice [12]. The recent finding of an inducible splicing variant of COX-1 (COX-3) can only further complicate the current controversy.
Further work is needed to target LOX enzymes chemoprevention, including the validation of these targets and the establishment of useful LOX modulators. It is important to clarify the mechanism by which LOX inhibition affects cell proliferation and apoptosis. The roles of 15-LOX and 8-LOX in pancreatic cancer development and growth still need to be clarified. Further studies may reveal new LOXs and new roles for known LOXs in the development and reversal of cancer and this will also help us to define a specific and effective LOX inhibitor for preventing pancreatic cancer.

Conclusion
COX and LOX metabolism of linoleic and arachidonic acids leads to the formation of a variety of metabolically active products with different roles in carcinogenesis. Our understanding of these roles is steadily increasing. This new information is providing a theoretical basis for development of new cancer chemoprevention approaches targeted to COX and LOX activity. Since no effective treatment is currently available for pancreatic cancer, blockade of the COX and LOX pathways might be valuable in the future for treating and preventing this dreadful disease.